Andrew N Phillips

发表

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

Amalio Telenti, Hansjakob Furrer, Manuel Battegay, 2002, AIDS.

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

Jonathan A C Sterne, Matthias Egger, Caroline A Sabin, 2006, The Lancet.

When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies

Caroline A Sabin, C. Sabin, A. Phillips, 2003, AIDS.

Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection

Caroline A Sabin, Clive Loveday, C. Sabin, 2003, AIDS.

The role of HIV in serious diseases other than AIDS

A. Phillips, J. Lundgren, J. Neaton, 2008, AIDS.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Hansjakob Furrer, Manuel Battegay, Pietro Vernazza, 2019, The Lancet.

Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial.

Stefan Esser, A. Phillips, E. Gardner, 2013, The Journal of infectious diseases.

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model

Deenan Pillay, D. Pillay, A. Phillips, 2008, The Lancet.

Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985–2002

Giovanni Rezza, A. Phillips, G. Rezza, 2005, AIDS.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Stephen R Cole, Jonathan A C Sterne, Ross Harris, 2009, The Lancet.

Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.

Caroline A Sabin, C. Sabin, A. Phillips, 2004, The Journal of infectious diseases.

HIV survival benefit associated with earlier antiviral therapy.

A. Mocroft, A. Phillips, J. Lundgren, 2004, Annals of internal medicine.

Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1–Positive Individuals

Caroline A Sabin, Schlomo Staszewski, B. Gazzard, 2004, Journal of acquired immune deficiency syndromes.

Combination antiretroviral therapy and the risk of myocardial infarction

Rodolphe Thiébaut, Peter Reiss, Nina Friis-Møller, 2003 .

The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy

Caroline A Sabin, Mike Youle, C. Sabin, 2003, AIDS.

Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era.

Christophe Fraser, Carel Pretorius, John Stover, 2015, The Lancet. Global health.

The per-protocol effect of immediate versus deferred antiretroviral therapy initiation

Haitao Chu, Stephen R Cole, Roger Logan, 2016, AIDS.

HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion

Giovanni Rezza, A. Phillips, P. Pezzotti, 1994, BMJ.

Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study

David Dunn, Kholoud Porter, John Walsh, 2008, AIDS.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

Sheena McCormack, Anne M Johnson, Christine Bowman, 2016, The Lancet.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Pietro Vernazza, Simon Collins, Gilles Wandeler, 2016, JAMA.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

Jonathan AC Sterne, Peter Reiss, Caroline A Sabin, 2002, The Lancet.